Tobin Juvenal Sells 1,301 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 1,301 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $38.39, for a total value of $49,945.39. Following the completion of the sale, the insider owned 77,694 shares of the company’s stock, valued at approximately $2,982,672.66. This represents a 1.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Up 0.2%

Shares of CSTL traded up $0.07 during midday trading on Thursday, reaching $30.47. 833,433 shares of the company were exchanged, compared to its average volume of 407,908. The stock has a 50-day moving average price of $23.38 and a 200-day moving average price of $26.23. The company has a market cap of $930.86 million, a price-to-earnings ratio of -46.17 and a beta of 0.98. Castle Biosciences, Inc. has a 1-year low of $17.72 and a 1-year high of $44.28. The company has a current ratio of 6.04, a quick ratio of 5.85 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL) last issued its earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.34. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%.The company had revenue of $99.86 million during the quarter, compared to the consensus estimate of $86.23 million. Research analysts expect that Castle Biosciences, Inc. will post -1.29 earnings per share for the current year.

Hedge Funds Weigh In On Castle Biosciences

A number of institutional investors have recently made changes to their positions in CSTL. Summit Partners Public Asset Management LLC boosted its stake in shares of Castle Biosciences by 164.7% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock valued at $41,184,000 after buying an additional 658,725 shares during the last quarter. SummitTX Capital L.P. increased its stake in shares of Castle Biosciences by 285.0% in the first quarter. SummitTX Capital L.P. now owns 67,033 shares of the company’s stock worth $1,646,000 after buying an additional 49,623 shares during the last quarter. Eventide Asset Management LLC bought a new stake in shares of Castle Biosciences in the fourth quarter worth $11,864,000. KBC Group NV acquired a new stake in Castle Biosciences in the first quarter valued at $907,000. Finally, SG Americas Securities LLC raised its holdings in Castle Biosciences by 1,051.8% in the first quarter. SG Americas Securities LLC now owns 244,886 shares of the company’s stock valued at $6,012,000 after acquiring an additional 223,624 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Castle Biosciences News Roundup

Here are the key news stories impacting Castle Biosciences this week:

• Positive Sentiment: BTIG raised its price target to $44 from $40 and reiterated a “buy” rating. The higher target reflects confidence in Castle Biosciences’ molecular-diagnostics growth prospects and implies meaningful upside from recent trading levels. BTIG raises Castle Biosciences price target
• Positive Sentiment: Castle’s latest quarterly performance exceeded expectations. Revenue reached $99.86 million versus the $86.23 million consensus estimate, while the loss of $0.07 per share was narrower than the expected $0.41 loss. The results support the view that operating performance is improving, although the company remains unprofitable.
• Positive Sentiment: Wall Street sentiment remains generally favorable, with an overall “Moderate Buy” consensus rating and an average price target of approximately $42. Institutional investors and hedge funds own about 92.6% of outstanding shares, while several funds recently increased their positions.
• Negative Sentiment: Several Castle Biosciences insiders sold shares. Derek J. Maetzold sold more than 39,000 shares across August 4–5, COO Kristen Oelschlager sold 8,586 shares, and Tobin W. Juvenal also reported a sale. The transactions reduced the executives’ holdings and could weigh on sentiment, particularly following the stock’s recent strength. However, the sales were conducted under pre-arranged Rule 10b5-1 plans, making them a less decisive bearish signal than discretionary selling. Castle Biosciences insider sales filing

Analyst Ratings Changes

A number of analysts have recently issued reports on CSTL shares. Roth Capital began coverage on shares of Castle Biosciences in a research note on Wednesday, June 24th. They set a “buy” rating and a $40.00 price objective on the stock. Robert W. Baird set a $36.00 target price on shares of Castle Biosciences in a research note on Friday, July 31st. Weiss Ratings raised shares of Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. Canaccord Genuity Group dropped their price target on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Finally, BTIG Research boosted their price objective on shares of Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Castle Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.